Purchase of 50% interest in West German firm Bioferon Biochemische Substanzen aimed at facilitating entry of Biogen's gamma interferon into West German and other markets, according to Biogen. Bioferon, which was a wholly owned subsidiary of Rentschler Pharmaceutical (West Germany), markets a beta interferon product, Fiblaferon, in West Germany for life threatening viral infections. Biogen says Fiblaferon, produced through traditional technologies, is "the first interferon product in the world to receive full regulatory approval.".
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.